More non-Q-wave myocardial infarctions but similar infarct sizes in patients with hypertension

Blood Pressure

Volumn 9, Issue 2-3, 2000, Pages 98-103

  Aursnes, Ivar ^a   Landmark, Knud ^a,b  

^a UNIVERSITY OF OSLO   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Antihypertensive therapy; Hypertension; Infarct size; Non Q wave infarcts

Indexed keywords

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORONARY RISK; FEMALE; HEART INFARCTION SIZE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

EID: 0034123435     PISSN: 08037051     EISSN: None     Source Type: Journal    
DOI: 10.1080/08037050050151799     Document Type: Article

References (36)

1. Herlitz J, Karlson BW, Richter A, Wiklund O, Jablonskiene D, Hjalmarson Å. Prognosis in hypertensives with acute myocardial infarction. J Hypertens 1992; 10: 1265-71.
2. Bache RJ. Effects of hypertrophy on coronary circulation. Progr Cardiovasc Dis 1988; 31: 403-40.
3. Fresco C, Avanzini F, Bosi S, et al. Prognostic value of a history of hypertension in 11 483 patients with acute myocardial infarction treated with thrombolysis. J Hypertens 1996; 14: 743-50.
4. Brush JE, Brand DH, Acampora D. Relation of peak creatine kinase levels during acute myocardial infarction to the presence or absence of previous manifestations of myocardial ischemia (angina pectoris or healed myocardial infarction). Am J Cardiol 1988; 62: 534-7.
5. Landmark K, Abdelnoor M, Urdal P, et al. Use of fish oils appears to reduce infarct size as estimated from peak creatine kinase and lactatate dehydrogenase activities. Cardiology 1998; 89: 94-102.
6. Koyanagi S, Eastham CL, Harrison DG, Marcus ML. Increased size of myocardial infarction in dogs with chronic hypertension and left ventricular hypertrophy. Circ Res 1982; 50: 55-62.
7. Marques-Vidal P, Tuomilehto J. Hypertension awareness, treatment and control in the community: is the "rule of halves" still valid? J Hum Hypertens 1997; 11: 213-20.
8. Gottdiener JS, Reda DJ, Massie BM, et al. for the VA Cooperative Study Group on Antihypertensive Agents. Effects of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension. Comparisons of six antihypertensive agents. Circulation 1997; 95: 2007-14.
9. Nakashima Y, Fouad FM, Tarazi RC. Regression of left ventricular hypertrophy from systemic hypertension by enalapril. Am J Cardiol 1984; 53: 1044-9.
10. Devereux RB. Do antihypertensive drugs differ in their ability to regress left ventricular hypertrophy? Circulation 1997; 95: 1983-5.
11. Verdecchia P, Schillaci G, Borgioni C, et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998; 97: 48-54.
12. Mosterd A, D'Agostino RB, Silberhatz H. et al. Trends in the prevalence of hypertension, antihypertensive therapy, and left ventricular hypertrophy from 1950 to 1989. N Engl J Med 1999; 340: 1221-7.
13. Berlowitz DR, Ash AS, Hickey EC, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med 1998; 339: 1957-63.
14. Hansson L. How far should blood pressure be lowered? What is the role of the J-curve? Am J Hypertens 1990; 3: 726-9.
15. Burt VL, Cutler JA, Higgins M, et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the Health Examination Surveys, 1960 to 1991. Hypertension 1995; 26: 60-9.
16. Mancia G, Sega R, Milesi C, Cesana G, Zanchetti A. Blood-pressure control in the hypertensive population. Lancet 1997; 349: 454-7.
17. Colhoun HM, Dong W, Poulter NR. Blood pressure screening, management and control in England: results from the health survey for England 1994. J Hypertens 1998; 16: 747-52.
18. Grande P, Christiansen C, Alstrup K. Comparison of ASAT, CK, CK-MB, and LD for the estimation of acute myocardial infarct size in man. Clin Chim Acta 1983; 128: 329-35.
19. Laarse van der A, Hermens WT, Hollaar L, et al. Assessment of myocardial damage in patients with myocardial infarction by serial measurement of serum alfa-hydroxybutyrate dehydrogenase levels. Am Heart J 1984; 107: 248-60.
20. Barbash GI, White HD, Modan M, et al, for the Investigators of the International Plasminogen Activator/ Streptokinase Mortality Trial. Significance of smoking in patients receiving thrombolytic therapy for acute myocardial infarction: experience gleaned from the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. Circulation 1993; 87: 53-8.
21. Grines CL, Topol EJ, O'Neill WW, et al. Effects of cigarette smoking on outcome after thrombolytic therapy for myocardial infarction. Circulation 1995; 91: 298-303.
22. Bates ER, Califf RM, Stack RS, et al, and the Thrombolysis and Angiography in Myocardial Infarction (TAMI-1) Trial. Influence of infarct location on arterial patency, left ventricular function and mortality. J Am Coll Cardiol 1989; 13: 12-8.
23. Casale PN, Devereux RB, Milner M, et al. Value of echocardiographic measurements of left ventricular mass in predicting cardiovascular events in hypertensive men. Ann Intern Med 1986; 105: 173-8.
24. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561-6.
25. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114: 345-52.
26. Burke AP, Farb A, Liang Y-H, Smialek J, Virmani R. Effect of hypertension and cardiac hypertrophy on coronary artery morphology in sudden cardiac death. Circulation 1996; 94: 3138-45.
27. Perticone F, Maio R, Ceravolo R, Cosco C, Cloro C, Mattioli PL. Relationship between left ventricular mass and endothelium-dependent vasodilation in never-treated hypertensive patients. Circulation 1999; 99: 1991-6.
28. Habib GB, Herbig J, Forman S. Influence of coronary collateral vessels on myocardial infarct size in humans: results of phase I thrombolysis in myocardial infarction (TIMI) trial. Circulation 1991; 83: 739-46.
29. Sabia PJ, Powers ER, Ragosta M, Sarembock IJ, Burwell LR, Kaul S. An association between collateral blood flow and myocardial viability in patients with recent myocardial infarction. N Engl J Med 1992; 327: 1825-31.
30. Landmark K, Aursnes I. Infarct size assessed by peak enzyme levels is reduced in patients using angiolensin-converting enzyme inhibitors at the onset of infarction. Submitted.
31. DiPasquale P, Paterna S, Cannizaro S, Bucca V. Does captopril in acute myocardial infarction attenuate reperfusion damage? Short-term and long-term effects. Int J Cardiol 1994; 43: 43-50.
32. Bussmann W-D, Micke G, Hildenbrand R, Klepzig R. Captopril in acute myocardial infarction: beneficial effects on infarct size and arrhythmias. Clin Cardiol 1995; 18: 465-70.
33. Søgaard P, Gøtzsche C-O, Ravkilde J, Nørgaard Aa, Thygesen K. Ventricular arrhythmias in acute and chronic phases after acute myocardial infarction. Effect of intervention with captopril. Circulation 1994; 90: 101-7.
34. Kannel WB, Gordon T, Offutt D. Left ventricular hypertrophy by electrocardiogram. Prevalence, incidence, and mortality in the Framingham study. Ann Intern Med 1969; 71: 90-105.
35. Dunn FG, Burns JMA, Hornung RS. Left ventricular hypertrophy in hypertension. Am Heart J 1991; 122: 312-5.
36. Messerli FH. Hypertension, left ventricular hypertrophy, ventricular ectopy, and sudden death. Am J Hypertens 1993; 6: 335-6.